Navigation Links
CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
Date:1/14/2009

Maturity Date Remains April 11, 2011, with $8.05 Conversion Price

SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's note holders had not exercised their "put" rights regarding the $5.25 million, 8% subordinated convertible debt securities. The terms of the notes provided an option under which the holders had an opportunity to elect, in January 2009, to be repaid in April 2009. Since the put option expired unexercised, the maturity date for the debt remains April 11, 2011. The convertible notes carry an 8% interest rate, payable in cash semi-annually with a conversion price of $8.05 per share.

"We are pleased that our debt holders have chosen to remain invested in CardioDynamics," stated Michael K. Perry, Chief Executive Officer. "We have seen continued improvement in our operating performance with seven consecutive quarters of revenue growth and an 83% reduction in operating loss over the past two years. Our objective for 2009 is to continue the positive growth trend and to achieve cash flow break-even for the full fiscal year."

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, positive growth trends, achievement of cash flow break-even and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
2. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
3. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
4. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
5. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
6. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
7. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
8. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
9. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2008 Results
11. Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 ... Research and Markets has announced ... - Industry Forecast to 2025" report to their offering. ... CAGR of around 1.8% over the next decade to reach approximately $12.8 ... market estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Medicine Technology: